Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02630082
Other study ID # 11704
Secondary ID
Status Completed
Phase N/A
First received August 24, 2015
Last updated December 10, 2015
Start date April 2011
Est. completion date March 2013

Study information

Verified date December 2015
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority Peru: Ethics CommitteePeru: Instituto Nacional de SaludUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

Rectal and genital sampling in HIV prevention trials permits assessments at the site of HIV entry. Yet the safety and acceptability of circumcision and sigmoidoscopy (and associated abstinence recommendations) are unknown in uncircumcised men who have sex with men (MSM) at high risk of HIV infection. The purpose of this study is to evaluate the feasibility of methods for assessing baseline characteristics of the mucosa of MSM at risk of HIV infection in Lima, Peru.


Description:

The worldwide HIV/AIDS epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. To fill gaps in the understanding of HIV vaccines, studies of mucosal immunity aim to complement assessments of systemic immunity. Yet it is unclear, and important to understand, how mucosal collections and the kinetics of immune activation they might initiate may impact peripheral blood endpoints in HIV vaccine trials. The HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID) are conducting a single-site, exploratory cohort study evaluating the feasibility of sampling mucosa and assessing cellular immune responses in sexually active men who have sex with men, a population in which later-phase HIV vaccine clinical trials are often conducted.

The primary purpose of HVTN 914 is to assess the feasibility of performing safe and tolerable circumcision and rectosigmoid biopsy studies on a study population of 30 healthy, HIV-seronegative, uncircumcised men in Lima, Peru, aged 21 to 30 years, who have sex with men and who are at high risk for acquisition of HIV; to assess institutional capacities to process mucosal samples; and to identify methods of evaluating foreskin and rectosigmoid mucosal immune responses that provide minimal variability for analysis of small sample sizes.

The study is designed to mimic an HIV vaccine study mucosal collection protocol. Participants agree to elective sigmoidoscopy biopsy collections and circumcision, and actively participate in this study for approximately 7 months. The primary analysis will focus on pre- and post-procedure retention, safety laboratory values, sexual satisfaction, HIV risk behaviors, and levels of activation markers associated with vulnerability to HIV infection in samples of peripheral blood mononuclear cells. A total of 11 study visits (including a screening visit) occur at Weeks 0-5, 10, and 26-28. Study procedures include physical exams, blood and urine collection, HIV testing, and questionnaire. Elective rectosigmoid bioscopy is performed at Weeks 2 and 27. Elective circumcision is performed at Week 4. Some blood collected from participants will be stored and used in future research. Risk-reduction counseling will be conducted at all study visits.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 21 Years to 30 Years
Eligibility Inclusion Criteria:

1. Male, age 21 to 30 years, who, in the 6 months prior to screening, experienced 1 or both of the following HIV risk criteria:

- unprotected anal intercourse with 1 or more male or MTF transgender partner(s); or

- anal intercourse with 2 or more male or MTF transgender partners. Note: Volunteers who have been in a monogamous relationship with an HIV-seronegative partner for > 6 months are excluded.

2. Ability and willingness to provide informed consent

3. Assessment of understanding: volunteer demonstrates understanding of the procedures and purpose of this study. Participants will complete a questionnaire prior to enrollment with verbal demonstration of understanding of all questionnaire items answered incorrectly.

4. Willingness to receive HIV test results

5. Willingness to discuss HIV infection risks (including sexual behavior and drug use) and amenable to HIV risk reduction counseling

6. Willingness to undergo phlebotomy, rectal swab, sigmoidoscopy, and circumcision

7. Willingness to adhere to safety protocols before and after sigmoidoscopy and circumcision

8. Agrees not to enroll in another study of an investigational research agent prior to completion of the last required protocol clinic visit

9. Hemoglobin = 13.0 g/dL

10. White blood cell (WBC) count = 3300 to 12,000 cells/mm3

11. Total lymphocyte count = 800 cells/mm3

12. Remaining differential either within institutional normal range or with site physician approval

13. Platelets = 125,000 to 550,000/mm3

14. Prothrombin time (PT) or partial thromboplastin time (PTT) = 1.25 institutional upper limit of normal; International Normalized Ratio (INR) = 1.5

15. Negative HIV-1 and -2 blood test: May use locally available assays that have been approved by HVTN Laboratory Operations.

Exclusion Criteria:

1. Volunteers who, in the six months prior to screening, have had sexual partners known to be HIV-infected

2. Volunteers who, for the 6 months prior to screening, have been in a monogamous relationship with an HIV-seronegative partner

3. History of immunodeficiency

4. Foreskin covering less than half the glans

5. Absolute medical indication for circumcision (balanitis or phimosis)

6. Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions). [This exclusion also applies to therapeutic anticoagulation that results in a prolonged PT/INR or PTT.]

7. HIV vaccine(s) received in a prior HIV vaccine trial. For potential participants who received control/placebo in an HIV vaccine trial, the HVTN 914 PSRT will determine eligibility on a case-by-case basis

8. Untreated clinical signs or symptoms of genitourinary or colonic infection

9. Any medical condition contraindicating circumcision or flexible sigmoidoscopy with biopsies

10. History of transactional sex (ie, exchange of sex for money, shelter, food, or drugs) in the preceding 6 months

11. Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety, or a participant's ability to give informed consent

12. History of keloid scarring

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label


Intervention

Procedure:
Circumcision

Flexible sigmoidoscopy


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Outcome

Type Measure Description Time frame Safety issue
Primary Pre- and post-procedure retention Number of enrolled trial participants that underwent each procedure visit and attended each follow-up visit 28 weeks Yes
Primary White blood cell counts White blood cells per mm^3 28 weeks Yes
Primary Hematocrit Hematocrit values measured as percentage 28 weeks Yes
Primary Hemoglobin Hemoglobin g/dL 28 weeks Yes
Primary Sexual satisfaction Sexual satisfaction during receptive, insertive sex, and abstinence periods using a CASI behavioral questionnaire (5 point Likert Scale) 28 weeks No
Primary HIV risk behaviors Sex without a condom according to a CASI behavioral questionnaire (Yes, No) 28 weeks Yes
Primary Levels of activation markers associated with vulnerability to HIV infection Levels of CCR5, ki67+ Bcl2low, and integrin alpha4beta7 expression on CD4+ CD3+ T cells collected in blood 28 weeks No
Primary Procedure-related events Number of procedure related events such as adverse drug reactions, hermorrage/hematoma, infection, pain, perforation/anatomic injury, and edema assessed for severity (NIH/NIAID DIvision of AIDS table for Grading of Severity of Adult and Pediatric Adverse Experiences). 28 weeks Yes
Primary Number of operational protocol deviations per mucosal sample Number of deviations per mucosal sample through study completion, an average of 7 months No
Primary Proportion of mucosal samples that are evaluable Percent of total samples (%) through study completion, an average of 7 months No
Primary Inter-person variability in mucosal responses Median and range of variables in peripheral blood mononuclear cells, foreskin, and rectosigmoid mucosa 28 weeks No
Primary Intra-person differences in mucosal responses obtained from the rectosigmoid colon Median and range of variables in peripheral blood mononuclear cells, foreskin, and rectosigmoid mucosa 28 weeks No
Primary Number of clinical protocol deviations per mucosal sample Number of deviations per mucosal sample through study completion, an average of 7 months No
Primary Number of laboratory protocol deviations per mucosal sample Number of deviations per mucosal sample through study completion, an average of 7 months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2